Ticker Details
Zymeworks Inc. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
IPO Date:	April 28, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.05B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.52 | 2.95%
Avg Daily Range (30 D):	$0.57 | 2.29%
Avg Daily Range (90 D):	$0.58 | 2.29%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.36M
Avg Daily Volume (90 D):	.46M

Trade Size
Avg Trade Size (Sh.):	93
Avg Trade Size (Sh.) (30 D):	48
Avg Trade Size (Sh.) (90 D):	49

Institutional Trades
Total Institutional Trades:	1,983
Avg Institutional Trade:	$1.83M
Avg Institutional Trade (30 D):	$1.81M
Avg Institutional Trade (90 D):	$2.54M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.59M
Avg Closing Trade (30 D):	$2M
Avg Closing Trade (90 D):	$2.45M
Avg Closing Volume:	99.35K

News

Jul 16, 2026 @ 10:00 AM Zymeworks to Report Second Quarter 2026 Financial ... Source: Na

Jun 29, 2026 @ 10:00 AM Zymeworks to Acquire Theravance Biopharma, Inc. Source: Na

Jun 14, 2026 @ 10:05 PM Zymeworks Presents New Phase 1 Data for Folate Rec... Source: Zymeworks Inc.

May 13, 2026 @ 10:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: Na

Apr 17, 2026 @ 7:00 PM Zymeworks Presents New Preclinical Data at AACR 20... Source: Zymeworks Inc.

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.62	$-.59	$-.55
Diluted EPS	$-.62	$-.59	$-.55
Revenue	$4.59M	$2.41M	$2.52M
Gross Profit
Net Income / Loss	$-45.02M	$-44.16M	$-41.21M
Operating Income / Loss	$-42.18M	$-47.12M	$-44.15M
Cost of Revenue
Net Cash Flow	$-64.87M	$203.13M	$-23.68M
PE Ratio